Royal Philips

The rating affirmation reflects Royal Philips' strong business profile, with strong diversification and leading positions in the majority of its addressable markets, as well as a solid financial risk profile with a conservative financial policy and an improving capital structure and earnings profile.

The Stable Outlook reflects Fitch Ratings' expectation that Philips' profitability and financial profile will continue to improve in the near term, building headroom to ensure that key ratios remain consistent with a 'BBB+' rating over the forecast horizon to 2027.

Key Rating Drivers

Litigation Agreement Reduces Risk: The agreement reached on 29 April 2024 to resolve the personal injury litigation and medical-monitoring class action lawsuit in the US related to Philips' Respironics respiratory devices reduces uncertainty and litigation risk for the company, lowering the risk to its existing Issuer Default Rating (IDR).

Fitch's updated rating case assumes that the agreement will be implemented as outlined by the company, with up to USD1.1 billion paid in 2025 under the settlement. We believe this can be comfortably absorbed within the existing 'BBB+' IDR, especially net of the expected EUR540 million in insurance payouts to be received in 2024.

Margin, Financial Policy to Drive Rating: The trajectory of the rating will be determined by the magnitude of the sustained improvement in margins and by capital allocation decisions, including M&A and cash-based shareholder remuneration. We believe Philips' Stable Outlook remains appropriate despite our expectation of improving leverage headroom under the 'BBB+' IDR, as we do not expect the group to reach our positive EBITDA margin and free cash flow (FCF) sensitivities in the next two years.

Profitability to Continue Recovering: Fitch-defined EBITDA margins (excluding non-recurring expenses related to the Respironics field action) improved to 11.2% in 2023 from 9.2% in 2022, as supply-chain issues abated.

Fitch expects margins to continue to rise gradually towards 14.5% by 2027, a level in line with 2021, prior to the decline in 2022 caused by the temporary impact of the recall of its Respironics devices, internal inefficiencies, global inflation spike and supply-chain issues. This expectation assumes that core end-markets remain favourable, continuing benefit from recent restructuring measures, and that cost discipline is maintained.

Stronger Cash Flow: Philips achieved a material improvement in its underlying operating cash flow generation, with funds from operations (FFO) margin up at 6.5% in 2023, from 2.6% in 2022. We expect this to continue in the short-to-medium term with FFO margins close to 10% over 2024-2027 on the back of operational improvements and better capacity utilisation FCF was strong in 2023 at around EUR1.3 billion (7% of revenue), helped by an exceptionally high working-capital inflow above EUR900 million.

We expect underlying FCF to remain in the low-to-mid single digits over 2024-2027, excluding one-off cash flow related the litigation (EUR430 million paid in 2024, EUR540 million insurance payout received in 2024 and USD1.1 billion paid in 2025). This assumes a modest impact from working-capital changes, although this hinges on Philips' capex and dividend policy.

Leverage: We expect deleveraging to be driven by a gradual recovery of margins towards pre-Covid-19 levels, with leverage potentially reaching Fitch's positive leverage sensitivity of 2.25x gross debt/EBITDA (Fitch-defined) in 2025. We expect gross and net leverage to continue to gradually improve in the next four years, to levels that will be strong for the present rating. We Corporates Diversified Manufacturing Netherlands

Ratings

Royal Philips

Long-Term IDR BBB+ Senior Unsecured Debt - Long-Term Rating BBB+

Outlooks

Long-Term Foreign-Currency Stable IDR

Click here for the full list of ratings

2035 Climate Vulnerability Signal: 35

Applicable Criteria

Corporates Recovery Ratings and Instrument Ratings Criteria (October 2023) Corporate Rating Criteria (November 2023) Sector Navigators – Addendum to the

Corporate Rating Criteria (November 2023)

Related Research

EMEA Diversified Industrials Outlook 2024 (December 2023) Global Medical Devices, Diagnostics and Products—Relative Credit Analysis (November 2023) Global Corporates Macro and Sector Forecasts

Analysts

Frank Orthbandt +44 20 3530 1037 frank.orthbandt@fitchratings.com

Xavier Taule Flores +34 93 492 9513 xavier.tauleflores@fitchratings.com expect gross and net leverage to improve to 2.5x and 1.5x, respectively, at end-2024 from 3.3x and 2.4x at end-2023, as a result of rising EBITDA but also some debt reduction.

Strong Business Profile: Fitch views Philips' business profile as strong and in line with its ratings. It is based on the company's position as a top-three medical equipment manufacturer in the world, a diverse product mix and end-customer base, and a material portion of revenue being generated by higher-margin services.

Along its leading positions in multiple growing and mature markets, Philips is well-positioned in the high-growth area of image-guided therapy, which benefits from hospitals investing more in ambulatory surgical centres and from growing interest in minimally invasive therapy. We believe Philips' strong position in this field will support solid organic growth in the medium term.

Financial Summary

(EURm)	2021	2022	2023	2024F	2025F	2026F
Gross revenue	17,156	17,827	18,169	18,482	19,284	20,277
EBITDA margin (%)	14.5	9.2	11.2	13.6	14.1	14.2
FFO margin (%)	10.4	2.6	6.5	9.6	9.7	9.8
EBITDA leverage (x)	2.3	4.4	3.3	2.5	2.3	2.4
EBITDA interest coverage (x)	19.8	9.2	9.1	12.8	15.2	18.0

Source: Fitch Ratings, Fitch Solutions

Rating Derivation Relative to Peers

Fitch does not see Philips as a pure medical devices manufacturer. Fitch sees its diagnosis & treatment and connected care businesses as a combination of medical devices and capital goods companies, which is complemented by its consumer personal health business.

Philips' direct competitors of similar scale, market reach and product portfolio include Siemens Healthineers and GE HealthCare Technologies Inc. (GE Health, BBB/Stable), which together represent roughly 70% of the medical imaging and ultrasound industry. Other medical device peers with comparable business and financial profiles include Boston Scientific Corporation (BBB+/Stable), Agilent Technologies, Inc. (BBB+/Stable), Becton, Dickinson & Company (BBB/Stable), Bio-Rad Laboratories Inc (BBB/Stable), Revvity, Inc. (BBB/Stable) and Baxter International Inc. (BAX: BBB-/Stable). Most of Fitch's 'BBB' rated issuers maintain EBITDA leverage of 2.5x-3.0x.

Philips' profitability lags behind that of most medical devices peers, including GE Health and Siemens Healthineers, but it is significantly stronger than that of most diversified manufacturing peers such as ABB Ltd. Philips has a record of managing a more conservative financial policy compared with most medical devices companies, including GE Health. Fitch expects Philips to maintain EBITDA net leverage at about 2.0x to 2026.

Navigator Peer Comparison

	IDR/Outlook	Operating Environment	Management and Corporate Governance	Revenue/Value Sources	Innovation	Market Position	Diversification	Profitability	Financial Structure	Financial Flexibility
Royal Philips	BBB+/Stable	aa-	a-	a	a	a	a-	bb-	a-	bbb+
Agilent Technologies, Inc.	BBB+/Stable	aa	a+	a-	a-	bbb+	a	a-	a	а
Baxter International Inc.	BBB-/Stable	aa	aa-	a-	bbb-	a-	a	bbb-	bbb-	bbb
Bio-Rad Laboratories Inc.	BBB/Stable	aa	bbb-	bbb-	bb+	bbb	bbb	bbb	a	a-
Boston Scientific Corporation	BBB+/Stable	aa	aa-	a 📕	a+	a	a	a	bbb+	а
Thermo Fisher Scientific Inc.	A-/Stable	aa	a	a-	a	a 📕	a 📃	a	a-	a-
GE Healthcare Holding LLC	BBB/Stable	aa	a+	a 📕	a-	a 📃	a	bb+	bbb	bbb+
Becton, Dickinson & Company	BBB/Stable	aa	aa-	a-	a-	a 📃	a	a-	bbb	a-
Revvity, Inc.	BBB/Stable	aa	a-	bbb	bbb	bbb	bbb	a-	bbb	bbb+
Source: Fitch Ratings.			I	Relative Importance of	of Factor	Higher	Moderate	Lower		

Name	IDR/Outlook	Operating Environment	Management and Corporate Governance	Revenue/Value Sources	Innovation	Market Position	Diversification	Profitability	Financial Structure	Financial Flexibility
Royal Philips	BBB+/Stable	+4	+1	+2	+2	+2	+1	-5	+1	0
Agilent Technologies, Inc.	BBB+/Stable	+5	+3	+1	+1	0	+2	+1	+2	+2
Baxter International Inc.	BBB-/Stable	+7	+6	+3	0	+3	+4	0	0	+1
Bio-Rad Laboratories Inc.	BBB/Stable	+6	-1	-1	-2	0	0	0	+3	+2
Boston Scientific Corporation	BBB+/Stable	+5	+4	+2	+3	+2	+2	+2	0	+2
Thermo Fisher Scientific Inc.	A-/Stable	+4	+1	0	+1	+1	+1	+1	0	0
GE Healthcare Holding LLC	BBB/Stable	+6	+4	+3	+2	+3	+3	-2	0	+1
Becton, Dickinson & Company	BBB/Stable	+6	+5	+2	+2	+3	+3	+2	0	+2
Revvity, Inc.	BBB/Stable	+6	+2	0	0	0	0	+2	0	+1
Source: Fitch Ratings.		Factor Score Relative	e to IDR	Worse positioned th	nan IDR	Withi	n one notch of IDR	Better	positioned than	IDR

Rating Sensitivities

Factors that Could, Individually or Collectively, Lead to Positive Rating Action/Upgrade

- EBITDA margin sustained above 15%
- Gross debt with equity credit below 2.25x operating EBITDA
- Cash from operations (CFO) less capex above 20% of gross debt
- FCF margin above 3% on a sustained basis

Factors that Could, Individually or Collectively, Lead to Negative Rating Action/Downgrade

- EBITDA margin sustained below 13%
- Gross debt with equity credit above 3x operating EBITDA
- CFO less capex below 15% of gross debt
- FCF margin below 2% on a sustained basis

Liquidity and Debt Structure

Liquidity Building Up: At end-2023, Philips had readily available cash of EUR1.7 billion (after Fitch restricts EUR200 million as unavailable for debt service) and full availability under its EUR1 billion revolver credit facility maturing in March 2029. In addition, Fitch forecasts positive FCF generation to 2027 of about EUR1 billion before acquisitions, which should continue to strengthen liquidity and financial flexibility ahead of any litigation payment.

Philips has funding characteristics in line with those of solid investment-grade companies, with solid access to financial markets and a well-spread senior unsecured debt maturity profile with no sizeable near-term refinancing needs.

ESG Considerations

The highest level of ESG credit relevance is a score of '3', unless otherwise disclosed in this section. A score of '3' means ESG issues are credit neutral or have only a minimal credit impact on the entity, either due to their nature or the way in which they are being managed by the entity. Fitch's ESG Relevance Scores are not inputs in the rating process; they are an observation on the relevance and materiality of ESG factors in the rating decision. For more information on Fitch's ESG Relevance Scores, visit https://www.fitchratings.com/topics/esg/products#esg-relevance-scores.


Climate Vulnerability Considerations

Fitch uses Climate Vulnerability Signals (Climate.VS) as a screening tool to identify sectors and Fitch-rated issuers that are potentially most exposed to credit-relevant climate transition risks and, therefore, require additional consideration of these risks in rating reviews. Climate.VS range from 0 (lowest risk) to 100 (highest risk). For more information on Climate.VS, see Fitch's Corporate Rating Criteria.

The FY23 revenue-weighted Climate Vulnerability Score (Climate.VS) for 2035 is 35 out of 100, suggesting moderate exposure to climate-related risks in that year. For further information on how Fitch perceives climate-related risks in Diversified Manufacturing sector see Industrials – Long-Term Climate Vulnerability Scores.

Climate.VS Evolution

As of Dec 31, 2023



Liquidity and Debt Maturities

Liquidity Analysis

(EURm)	2024F	2025F	2026F	2027F
Available liquidity				
Beginning cash balance	1,869	3,339	2,043	607
Rating case FCF after acquisitions and divestitures	1,343	-418	-372	-121
Debt issued since last balance sheet	700			
Share repurchases	-130	-130	-200	-200
Total available liquidity (a)	3,782	2,791	1,471	286
Liquidity uses				
Debt maturities	-444	-748	-864	-750
Total liquidity uses (b)	-444	-748	-864	-750
Liquidity calculation				
Ending cash balance (A+B)	3,339	2,043	607	-464
Revolver availability	1,000	1,000	0	0
Ending liquidity	4,339	3,043	607	-464
Liquidity score (x)	9.5	5.2	1.9	0.6
F - Forecast. Source: Fitch Ratings, Fitch Solutions, Royal Philips				
Scheduled debt maturities				
(EURm)				31-Dec-2023
2024				444

2024	444
2025	748
2026	864
2027	750
2028	500
Thereafter	4,059
Total	7,364
Source: Fitch Ratings, Fitch Solutions, Royal Philips	

Key Assumptions

Fitch's Key Assumptions Within our Rating Case for the Issuer:

- Mid-single-digit organic revenue growth to 2027, supported by all divisions
- Fitch-defined EBITDA margin rising to 13.5% in 2024 and gradually improving towards 14.5% by 2027. Oneoff expenses related to the Respironics field action excluded from Fitch-defined EBITDA
- Litigation insurance payout of EUR540 million received in in 2024 and USD1.1 billion litigation payout paid in 2025
- Capex at about 4% of revenue in 2024 and about 4.5% for 2025-2027
- Modest working-capital inflow in 2024 followed by modest working capital outflows to 2027
- Cash dividend payments to resume in 2026 broadly at the level of 2022
- No material acquisitions until 2026 and EUR500 million per year thereafter
- Modest share buybacks at about EUR130 million per year in 2024 and 2025, before increasing modestly from 2026

Financial Data

(EURm)	2021	2022	2023	2024F	2025F	2026F
Summary income statement						
Gross revenue	17,156	17,827	18,169	18,482	19,284	20,277
Revenue growth (%)	-0.9	3.9	1.9	1.7	4.3	5.2
EBITDA before income from associates	2,483	1,646	2,029	2,508	2,718	2,884
EBITDA margin (%)	14.5	9.2	11.2	13.6	14.1	14.2
EBITDA after associates and minorities	2,495	1,652	2,039	2,516	2,726	2,892
EBIT	1,412	258	969	1,249	1,435	1,544
EBIT margin (%)	8.2	1.4	5.3	6.8	7.4	7.6
Gross interest expense	-135	-233	-229	-197	-180	-161
Pretax income including associate income/loss	509	-1,730	-524	441	761	972
Summary balance sheet						
Readily available cash and equivalents	2,103	972	1,669	2,439	1,843	1,907
Debt	5,796	7,289	6,662	6,219	6,171	6,807
Net debt	3,693	6,317	4,993	3,780	4,328	4,900
Summary cash flow statement						
EBITDA	2,483	1,646	2,029	2,508	2,718	2,884
Cash interest paid	-126	-180	-223	-197	-180	-161
Cash tax	-249	-333	-152	-233	-381	-431
Dividends received less dividends paid to minorities	12	6	10	8	8	8
Other items before FFO	-346	-684	-537	-350	-350	-350
FFO	1,791	470	1,180	1,778	1,874	1,991
FFO margin (%)	10.4	2.6	6.5	9.6	9.7	9.8
Change in working capital	-414	-862	913	200	-100	-150
CFO (Fitch-defined)	1,377	-392	2,093	1,978	1,774	1,841
Total non-operating/nonrecurring cash flow	85	_	-160	125	-1,223	-300
Capex	-763	-806	-644	_	_	_
Capital intensity (capex/revenue) (%)	4.4	4.5	3.5	_	_	_
Common dividends	-482	-412	-2	_	_	_
FCF	217	-1,610	1,287	_	_	_
FCF margin (%)	1.3	-9.0	7.1	_	_	_
Net acquisitions and divestitures	361	-588	7	_	_	_
Other investing and financing cash flow items	365	151	245	_	_	_
Net debt proceeds	-251	1,091	-181	-444	-48	636
Net equity proceeds	-1,613	-175	-662	-130	-130	-200
Total change in cash	-921	-1,131	696	770	-596	64
Calculations for forecast publication						
Capex, dividends, acquisitions and other items before FCF	-799	-1,806	-799	-635	-2,193	-2,213
FCF after acquisitions and divestitures	578	-2,198	1,294	1,343	-418	-372
FCF margin after net acquisitions (%)	3.4	-12.3	7.1	7.3	-2.2	-1.8
Gross Leverage ratios (x)						
EBITDA leverage	2.3	4.4	3.3	2.5	2.3	2.4
CFO-capex/debt	10.6	-16.4	21.8	19.6	14.7	13.6
Net Leverage ratios (x)						
EBITDA net leverage	1.5	3.8	2.4	1.5	1.6	1.7
CFO-capex/net debt	16.6	-19.0	29.0	32.3	20.9	18.9
Coverage ratios (x)						
EBITDA interest coverage	19.8	9.2	9.1	12.8	15.2	18.0
CFO - Cash flow from operations	9					



How to Interpret the Forecast Presented

The forecast presented above is based on Fitch Ratings' internally produced, conservative rating case forecast. It does not represent the forecast of the rated issuer. The forecast set out above is only one component used by Fitch Ratings to assign a rating or determine a rating outlook, and the information in the forecast reflects material but not exhaustive elements of Fitch Ratings' rating assumptions for the issuer's financial performance. As such, it cannot be used to establish a rating, and it should not be relied on for that purpose. Fitch Ratings' forecasts are constructed using a proprietary internal forecasting tool, which employs Fitch Ratings' own assumptions on operating and financial performance that may not reflect the assumptions that you would make. Fitch Ratings' own definitions of financial terms such as EBITDA, debt or free cash flow may differ from your own such definitions. Fitch Ratings may be granted access, from time to time, to confidential information on certain elements of the issuer's forward planning. Certain elements of such information may be omitted from this forecast, even where they are included in Fitch Ratings' own internal deliberations, where Fitch Ratings, at its sole discretion, considers the data may be potentially sensitive in a commercial, legal or regulatory context. The forecast (as with the entirety of this report) is produced strictly subject to the disclaimers set out at the end of this report. Fitch Ratings may update the forecast in future reports but assumes no responsibility to do so. Original financial statement data for historical periods is processed by Fitch Ratings are generated by rating agency staff.

Ratings Navigator

Fite	hRatings		Royal Ph	nilips			ESG Relevance:		Corp Medical	orates Ratin Devices, Diagnos	gs Navigator stics and Products
Frankra					Business Profile				Financial Profile		
Factor Levels	Sector Risk Profile	Operating Environment	Management and Corporate Governance	Revenue/Value Sources	Innovation	Market Position	Diversification	Profitability	Financial Structure	Financial Flexibility	Issuer Default Rating
aaa											AAA
aa+											AA+
aa											AA
aa-		- T -									AA-
a+	T I			- T		T					A+
a							- T				A
a-				- - -						T	A-
bbb+											BBB+ Stable
bbb										- 1	BBB
bbb-											BBB-
bb+											BB+
bb								- T			BB
bb-											BB-
b+											B+
b											в
b-											В-
ccc+											ccc+
ccc											ccc
ccc-											ccc-
cc											сс
c											с
d or rd											D or RD

Bar Chart Legend:					
Vertical Bars = Range of Rating Factor	Bar Arrows = Rating Factor Outlook				
Bar Colors = Relative Importance	☆ Positive				
Higher Importance					
Average Importance	1 Evolving				
Lower Importance	□ Stable				

FitchRatings

Corporates Ratings Navigator Medical Devices, Diagnostics and Products

perating	g Environment	_		Manag	jemei	nt and Corporate Governan	ce						
a	Economic Environment	а	Strong combination of countries where economic value is created and where assets are located.	a+		Management Strategy	bbb	Strategy may include opportunistic elements but	soundly impl	emented.			
a-	Financial Access	aa	Very strong combination of issuer specific funding characteristics and of the strength of the relevant local financial market.	а	T	Governance Structure	а	Experienced board exercising effective check and several shareholders.	balances. C	wnership	can be cor	ncentrate	d am
	Systemic Governance	aa	Systemic governance (eg rule of law, corruption; government effectiveness) of the issuer's country of incorporation consistent with 'aa'.	a -		Group Structure	а	Group structure shows some complexity but mitig	gated by tran	sparent re	porting.		
)-				bbb+	L.	Financial Transparency	а	High quality and timely financial reporting.					
cc+				bbb									
evenue/	Value Sources			Innova	tion								
aa-	Product Strength	а	Large majority of revenues derived from products/technological platforms that have top-three market positions.	aa-		Breadth and Depth	а	New product flow plus currently marketed product meaningful new product/platform introductions.	s sufficient fi	or roughly	four years	of consis	tent a
a+	Number of Competitors	а	Four meaningful competitors for the majority of product/technological platform sales	a+	T	Sufficiency for Profitable Growth	а	Internal R&D and existing portfolio sufficient to dri	ve growth at	or above t	he market.		
а	Level of Differentiation	bbb	Majority of expected revenues to be derived from highly differentiated products/technological platforms.	а									
a-				8-	Т								
bb+				bbb+									
arket Po	osition			Divers	ificat	ion							
aa-	Revenue	а	\$12 billion	a+		Geographic Diversification	а	Meaningful presence in three of the following mark	kets: U.S., E	urope, Ja	oan and en	nerging m	narkets
a+	EBITDA	а	S1 billion	а	T	Product Diversification	bbb	Credit profile able to withstand significant and dur platform.	able operatio	nal press	ire in its to	p techno	logical
a	Market Position	а	Strong global market positions.	a-									
a-				bbb+	Т								
bb+				bbb									
rofitabili	ity			Financ	ial St	tructure							
b+	EBITDA Margin	b	17%	a+		EBITDA Leverage	а	2.5x					
bb	EBIT Margin	b	11%	а	T	EBITDA Net Leverage	а	2.0x					
bb-	FCF Margin	bb	5%	a-		(CFO-Capex)/Debt	bbb	12.5%					
b+	Volatility of Profitability	bb	Higher volatility of profits than industry average.	bbb+	Т								
b				bbb									
nancial	Flexibility			Credit	-Rele	vant ESG Derivation						Over	rall F
а	Financial Discipline	а	Clear commitment to maintain a conservative policy with only modest deviations allowed.	Royal Ph	ilips has	s 9 ESG potential rating drivers			key driver	0	issues	5	Ē
a-	Liquidity	bbb	One-year liquidity ratio above 1.25x. Well-spread maturity schedule of debt but funding may be less diversified.		•	Management of product lifecycle and p management - product	otential ir	npact on food/water supply; supply chain					E
bb+	EBITDA Interest Coverage	а	9.0x		•	Affordability			driver	0	issues	4	F
bb	FX Exposure	bbb	Some exposure of profitability to FX movements and/or debt/cash-flow match. Effective hedging in place.		•	Product safety; ethical marketing			potential driver	9	issues	3	
bb-					•	Impact of labor negotiations and emplo	oyee (dis)	satisfaction	anver				
					•	Pressure to contain healthcare spendi	ng growtł	r; highly sensitive political environment	not a	3	issues	2	
			ee-notch band assessment for the overall Factor, illustrated by a bar. The ith a description appropriate for each Sub-Factor and its corresponding			Governance is minimally relevant to th	e rating a	nd is not currently a driver.	rating driver	2	issues	1	

How to Read This Page: The left column shows the three-notch band assessment for the overall Factor, illustrated by a bar. The right column breaks down the Factor into Sub-Factors, with a description appropriate for each Sub-Factor and its corresponding category.

Royal Philips

For further details on Credit-Relevant ESG scoring, see page 3.

ce to

Credit Rating

5

4

3

2

1

FitchRatings

Corporates Ratings Navigator Medical Devices, Diagnostics and Products

0

0

9

3

2

issues

issues

issues

issues

issues

key driver

drive

potential driver

Credit-Relevant ESG Derivation

Royal Philips has 9 ESG potential rating drivers

Royal Philips has exposure to waste & impact management risk but this has very low impact on the rating

Royal Philips

- Royal Philips has exposure to access/affordability risk but this has very low impact on the rating.
- Royal Philips has exposure to product safety/ethical marketing risk but this has very low impact on the rating
- Royal Philips has exposure to labor relations & practices risk but this has very low impact on the rating.
- Royal Philips has exposure to social pressure to contain costs but this has very low impact on the rating
- Governance is minimally relevant to the rating and is not currently a driver.

Environmental (E) Relevance Scores

General Issues	E Score	Sector-Specific Issues	Reference	ER	Relev
GHG Emissions & Air Quality	1	n.a.	n.a.	5	
Energy Management	2	Energy use in manufacturing	Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility	4	
Water & Wastewater Management	2	Water usage in manufacturing process	Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility	3	
Waste & Hazardous Materials Management; Ecological Impacts		Management of product lifecycle and potential impact on food/water supply; supply chain management - product	Product Portfolio; Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility	2	
Exposure to Environmental Impacts	2	Manufacturing facilities and inventory exposure to extreme weather events	Product Portfolio; Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility	1	

Social (S) Relevance Scores

Gov Mana

Gove

Grou

Financial Transparency

General Issues	S Score	Sector-Specific Issues	Reference
Human Rights, Community Relations, Access & Affordability	3	Affordability	Product Portfolio; Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility
Customer Welfare - Fair Messaging, Privacy & Data Security	3	Product safety; ethical marketing	Product Portfolio; Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility
Labor Relations & Practices	3	Impact of labor negotiations and employee (dis)satisfaction	Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility
Employee Wellbeing	1	n.a.	n.a.
Exposure to Social Impacts		Pressure to contain healthcare spending growth; highly sensitive political environment	Scale and Competitive Position; R&D Profile; Profitability; Financial Structure; Financial Flexibility

evance

5 4 3 2 1

5

4 3

2

1

Management and Corporate Governance

How to Read This Page
 ESG relevance scores range from 1 to 5 based on a 15-level color gradation. Red (5) is most relevant to the credit rating and green (1) is least relevant.
 The Environmental (E), Social (B) and Governance (G) tables break out the ESG general issues and the soctor-specific issues that are most relevant to each industry group. Relevance scores are assigned to each sector-specific issues to the sector-specific issues to the sector-specific issues to the sector-specific issues to the relevance of the sector specific issues to the relevance scores are assigned to each sector-specific issues to the sector-specific issues to the issuer's overal color base are visualizations of the frequency of occurrence of the highest constituent relevance scores. They do not represent an aggregate of the relevance. Secores or aggregate ESG credit relevance.
 The Credit-Relevant ESG Derivation table's far right column is a visualization of the frequency of occurrence of the highest ESG relevance scores across the combined E, S and G categories. The three columns to the left of ESG Relevance to Credit Rating summarize rating relevance scoreal arrange to relevance scores across and the relevance scores.
 Al scores of '4' and '5' are assumed to reflect a negative impact unless indicated with a '* sing for positive impact.
 Classification of ESG issues has been developed from Fitch's sector ratings criteria. The General Issues and Sector-Specific Issues frave on the classification standards published by the United Nations Principles for Responsible Investing (RPAI), the Sustainability Accounting Standards Board (SASB), and the Word Bank.


CREDIT-RELEVANT ESG SCALE

	CREDIT-RELEVANT ESG SCALE
Hov	v relevant are E, S and G issues to the overall credit rating?
5	Highly relevant, a key rating driver that has a significant impact on the rating on an individual basis. Equivalent to "higher" relative importance within Navigator.
4	Relevant to rating, not a key rating driver but has an impact on the rating in combination with other factors. Equivalent to "moderate" relative importance within Navigator.
3	Minimally relevant to rating, either very low impact or actively managed in a way that results in no impact on the entity rating. Equivalent to "lower" relative importance within Navigator.
2	Irrelevant to the entity rating but relevant to the sector.
1	Irrelevant to the entity rating and irrelevant to the sector.

tomer Welfare - Fair Messaging, Privacy & Security	3	Product safety; ethical marketing	Product Portfolio; Scale and Competitive Position; Profitability; Financial Structure; Financial Flexibility
or Relations & Practices	3	Impact of labor negotiations and employee (dis)satisfaction	Scale and Competitive Position; Profitability; Financia Structure; Financial Flexibility
loyee Wellbeing	1	n.a.	n.a.
osure to Social Impacts	3	Pressure to contain healthcare spending growth; highly sensitive political environment	Scale and Competitive Position; R&D Profile; Profita Financial Structure; Financial Flexibility
vernance (G) Relevance Scor			
vernance (G) Relevance Scor	es		
General Issues	G Score	Sector-Specific Issues	Reference
		Sector-Specific Issues Strategy development and implementation	Reference Management and Corporate Governance
General Issues	G Score		

3 Quality and timing of financial disclosure

Simplified Group Structure Diagram



Source: Fitch Ratings, Fitch Solutions, Royal Philips as at May 2023

Peer Financial Summary

Company	lssuer Default Rating	Financial statement date	Gross revenue (EUR Millions)	EBITDAR margin (%)	FCF margin (%)	EBITDA E leverage (x)	BITDA interest coverage (x)
Royal Philips	BBB+						
	BBB+	2023	18,169	11.2	7.1	3.3	9.1
	A-	2022	17,827	9.2	-9.0	4.4	9.2
	A-	2021	17,156	14.5	1.3	2.3	19.8
GE HealthCare Technologies Inc.	BBB						
	BBB	2023	17,846	17.5	8.6	2.8	6.0
	BBB(EXP)	2022	17,196	17.6	9.8	2.6	59.9
		2021	15,548	19.7	7.7	0.0	164.8
Thermo Fisher Scientific Inc.	A-	·					
	A-	2023	39,117	25.8	14.9	3.2	8.0
	BBB+	2022	42,110	27.2	14.4	2.8	18.3
	BBB+	2021	34,669	33.6	16.3	2.7	23.8
Agilent Technologies, Inc.	BBB+						
	BBB+	2023	6,435	29.9	17.7	1.3	23.0
	BBB+	2022	6,907	30.8	11.3	1.3	24.8
	BBB+	2021	5,426	29.2	16.8	1.5	24.3
Boston Scientific Corporation	BBB+						
	BBB+	2023	12,997	28.3	11.9	2.4	15.6
	BBB+	2022	11,890	30.4	6.9	2.4	8.6
	BBB	2021	10,511	28.1	10.8	2.8	9.9
Becton, Dickinson & Company	BBB						
	BBB	2023	18,286	27.8	5.0	3.0	11.9
	BBB	2022	19,358	27.1	2.0	3.2	13.1
	BBB-	2021	17,487	28.6	12.3	3.1	12.2
Bio-Rad Laboratories Inc.	BBB						
	BBB	2023	2,438	20.7	9.5	2.0	12.6
	BBB	2022	2,627	24.5	3.8	1.7	30.4
	BBB	2021	2,556	25.2	19.2	_	514.1

Source: Fitch Ratings, Fitch Solutions

Fitch Adjusted Financials

(EURm as of 31 Dec 23)	Notes and formulas	Standardised values	Cash adjustment	Lease treatment	Other adjustments	Adjusted values
Income statement summary						
Revenue		18,169	_	_	_	18,169
EBITDA	(a)	1,156	_	-228	1,101	2,029
Depreciation and amortization		-1,261	_	201	_	-1,060
EBIT		-105	_	-27	1,101	969
Balance sheet summary						
Debt	(b)	7,689	_	-1,074	47	6,662
Of which other off-balance-sheet debt		_	_	_	_	_
Lease-equivalent debt		_	_	_	_	_
Lease-adjusted debt		7,689	_	-1,074	47	6,662
Readily available cash and equivalents	(c)	1,869	-200	_	_	1,669
Not readily available cash and equivalents		_	200	_	_	200
Cash flow summary						
EBITDA	(a)	1,156	_	-228	1,101	2,029
Dividends received from associates less dividends paid to minorities	(d)	10	_	_	_	10
Interest paid	(e)	-250	_	27	_	-223
Interest received	(f)	53	_	_	_	53
Preferred dividends paid	(g)	_	_	_	_	_
Cash tax paid		-152	_	_	_	-152
Other items before FFO		404	_	_	-941	-537
FFO	(h)	1,221	_	-201	160	1,180
Change in working capital		913	_	_	_	913
CFO	(i)	2,134	_	-201	160	2,093
Non-operating/nonrecurring cash flow		_	_	_	-160	-160
Сарех	(j)	-644	_	_	_	-644
Common dividends paid		-2	_	_	_	-2
FCF		1,488	_	-201	_	1,287
Gross leverage (x)						
EBITDA leverage	b/(a+d)	6.6	_	_	_	3.3
(CFO-capex)/debt (%)	(i+j)/b	19.4	_	_	_	21.8
Net leverage (x)						
EBITDA net leverage	(b-c)/(a+d)	5.0	_	_	_	2.4
(CFO-capex)/net debt (%)	(i+j)/(b-c)	25.6	_	_	_	29.0
Coverage (x)						
EBITDA interest coverage	(a+d)/(-e)	4.7	_	_	_	9.1

CFO - Cash flow from operations

Note: The standardised items presented above are based on Fitch's taxonomy for the given sector and region.

Reported items may not match the Fitch taxonomy, but they are captured into corresponding lines accordingly.

Debt includes other off-balance-sheet debt.

Source: Fitch Ratings, Fitch Solutions, Royal Philips

SOLICITATION & PARTICIPATION STATUS

For information on the solicitation status of the ratings included within this report, please refer to the solicitation status shown in the relevant entity's summary page of the Fitch Ratings website.

For information on the participation status in the rating process of an issuer listed in this report, please refer to the most recent rating action commentary for the relevant issuer, available on the Fitch Ratings website.

DISCLAIMER & DISCLOSURES

All Fitch Ratings (Fitch) credit ratings are subject to certain limitations and disclaimers. Please read these limitations and disclaimers by link: https://www.fitchratings.com/understandingcreditratings. following following this In addition, the https://www.fitchratings.com/rating-definitions-document details Fitch's rating definitions for each rating scale and rating categories, including definitions relating to default. Published ratings, criteria, and methodologies are available from this site at all times. Fitch's code of conduct, confidentiality, conflicts of interest, affiliate firewall, compliance, and other relevant policies and procedures are also available from the Code of Conduct section of this site. Directors and shareholders' relevant interests are available at https://www.fitchratings.com/site/regulatory. Fitch may have provided another permissible or ancillary service to the rated entity or its related third parties. Details of permissible or ancillary service(s) for which the lead analyst is based in an ESMA- or FCA-registered Fitch Ratings company (or branch of such a company) can be found on the entity summary page for this issuer on the Fitch Ratings website.

In issuing and maintaining its ratings and in making other reports (including forecast information), Fitch relies on factual information it receives from issuers and underwriters and from other sources Fitch believes to be credible. Fitch conducts a reasonable investigation of the factual information relied upon by it in accordance with its ratings methodology, and obtains reasonable verification of that information from independent sources, to the extent such sources are available for a given security or in a given jurisdiction. The manner of Fitch's factual investigation and the scope of the third-party verification is ubtains will vary depending on the nature of the rated security and the scope of the third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third-party verifications such as audit reports, agreed-upon procedures letters, appraisals, actuarial reports, engineering reports, legal opinions and other reports provided by third parties, the availability of independent and competent third-party verification such as audit reports, agreed-upon procedures letters and that neither an enhanced factual investigation nor any third-party verification can ensure that all of the information Fitch relies on in connection with a rating or a report will be accurate and complete. Ultimately, the issuer and its advisers are responsible for the accuracy of the information they provide to Fitch and to the market in offering documents and other reports. In issuing its ratings and its reports, Fitch must rely on the work of experts, including independent auditors with respect to legal and tax matters. Further, ratings and forecasts of financial and other information or current facts, ratings and forecasts can be verified as facts. As a result, despite any verification or current facts, ratings and forecasts can be verified by future events or conditions that were not anticipated at the time a rating

The information in this report is provided "as is" without any representation or warranty of any kind, and Fitch does not represent or warrant that the report or any of its contents will meet any of the requirements of a recipient of the report. A Fitch rating is an opinion as to the creditworthiness of a security. This opinion and reports made by Fitch and no individual, or group of individuals, is solely responsible for a rating or a report. The rating does not address the risk of loss due to risks other than credit risk, unless such risk is specifically mentioned. Fitch is not engaged in the offer or sale of any security. All Fitch reports have shared authorship. Individuals identified in a Fitch report were involved in, but are not solely responsible for, the opinions stated therein. The individuals are named for contact purposes only. A report providing a Fitch rating is neither a prospectud in, but are not solely responsible for any reason in the sole discretion of Fitch. Fitch does not provide investment advice of any security. Ratings are not a recommendation to buy, sell, or hold any security. Fitch receives fees from issuers, insurers, guarantors, other obligors, and underwriters for rating securities. Such fees generally vary from US\$1,000 to US\$750,000 (or the applicable currency equivalent) fees are expected to vary from US\$1,000 to US\$1,500,000 (or the applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with regular of uses in such as a security. The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with applicable currency equivalent). The assignment, publication, or dissemination of a rating by Fitch shall not constitute a consent by Fitch to use its name as an expert in connection with applicable currency equivalent. The assignment, publication, or dissemination of a rati

For Australia, New Zealand, Taiwan and South Korea only: Fitch Australia Pty Ltd holds an Australian financial services license (AFS license no. 337123) which authorizes it to provide credit ratings to wholesale clients only. Credit ratings information published by Fitch is not intended to be used by persons who are retail clients within the meaning of the Corporations Act 2001.

Fitch Ratings, Inc. is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (the "NRSRO"). While certain of the NRSRO's credit rating subsidiaries are listed on Item 3 of Form NRSRO and as such are authorized to issue credit ratings on behalf of the NRSRO (see https://www.fitchratings.com/site/regulatory), other credit rating subsidiaries are not listed on Form NRSRO (the "non-NRSROs") and therefore credit rating subsidiaries are not listed on Form NRSRO (the "non-NRSROs") and therefore credit ratings issued by those subsidiaries are not issued on behalf of the NRSRO.

Copyright © 2024 by Fitch Ratings, Inc., Fitch Ratings Ltd. and its subsidiaries. 33 Whitehall Street, NY, NY 10004. Telephone: 1-800-753-4824, (212) 908-0500. Reproduction or retransmission in whole or in part is prohibited except by permission. All rights reserved.